Status: Recruiting
Mirdametinib in Histiocytic Disorders
The purpose of this study is to see if treatment with mirdametinib in patients with Langerhans cell histiocytosis (LCH) or other histiocytic disorders will be better than current treatments and with fewer side effects.
Participants needed: 40
Trial details
Phase: Phase 2Age: 2+Biological sex: AllType: InterventionalSponsor: Children's Hospital Medical Center, CincinnatiUpdated: Sep 16, 2025Locations: 1
Eligibility criteria
Subjects must be ≥ 2 years of age AND have a diagnosis of a histiocytic disorder... [+8]
Myelosuppressive Chemotherapy: Must not have received any cytotoxic chemotherapy... [+11]